Mean plasma total immunoreactivetstrogens and luteinizing hormone levels in 4 thyrotoxic and 6 euthyroid females in phases of the menstrual cycle results, therefore, represent the total immunoreactive aestrogens. The antiserum (a gift from Dr G E Abrahams) is specific for cestrogens and reacts with cestradiol-17,B more than any other cestrogen. There was no significant cross reaction with other steroids. The water blank for the method was 5.0±1.8 pg/ml. The results were corrected for the water blank. The recovery of cestradiol added to water was 98±5% and to pooled plasma obtained from male subjects was 94±4% over the range 100-1000 pg. The LH assays were performed by the double antibody radioimmunoassay technique described by Midgley (1966) and modified in Oxford (Naftolin 1970 ) by a further extension of the incubation period. All samples from one patient were estimated in the same assay in duplicate. Most assays included specimens from euthyroid controls as well as thyrotoxic patients. The second international reference preparation of the human menopausal gonadotrophin was used as standard.
Results
Plasma total immunoreactive cestrogen concentrations were raised in all the thyrotoxics. The mean levels in the follicular and luteal phases in 4 patients with hypomenorrhoea were 28.1 ±3.4 ng/ 100 ml and 36.0 ±9.4 ng/100 ml respectively in comparison with normal values of 13.1 ± 1.6 ng/100 ml and 22.3±2.1 ng/100 ml (Table 1 ). In this group of patients and in all the normal controls an cestrogen peak occurred the day before the LH peak. However, in 2 thyrotoxic patients who had just developed amenorrhcea cestrogen peaks occurred without ensuing LH peaks.
Plasma LH levels were also raised in all the thyrotoxic patients (Table 1 ). In the 4 thyrotoxics with hypomenorrhaea the mean LH levels in the follicular and luteal phases of the cycle were 23.7±2.9 miu/ml IRP-2 HMG and 22.3 ±2.8 miu/ml respectively in comparison to normal values of 10.9 ± 1.0 miu/ml and 9.0± 1.5 miu/ml. In the 2 thyrotoxics with amenorrhoea the LH values were also raised (mean 21.3±1.6 miu/ml) but interestingly showed greater day-to-day variability than in menstruating women. Midcycle LH peaks were present in hypomenorrhceic thyrotoxics but not in those who had developed amenorrhcea.
One possible explanation for these observations is that in thyrotoxicosis the feedback effects of cestrogen on the hypothalamo-pituitary LH releasing apparatus (negative and positive 'feedbacks') are blunted. To test this hypothesis, small doses of aestradiol benzoate (125 and 250 ,ug) were injected into postmenopausal euthyroid and thyrotoxic females. The results obtained from these tests show a greater suppressibility of LH in response to aestradiol injection in euthyroid compared to thyrotoxic postmenopausal females.
An alternative explanation of all the results could stem from the large increase in cestrogen binding globulins in thyrotoxicosis. With the realization of the importance of 3'5'adenosine cyclic monophosphate (C-AMP) in mediating the cellular response to many hormones (Robison et al. 1968 , Jost & Rickenberg 1971 has come the need for a simple rapid assay for the (Gillman 1970 , Brown et al. 1971 . We have investigated the efficacy of a bovine adrenal preparation for determination of C-AMP changes in human adipose tissue in vitro and in vivo. Initial testing of the bovine adrenal preparation revealed in it significant levels of both adenyl cyclase and phosphodiesterase activity (Fig 1) , both under assay conditions and when augmented by addition of 10 mmol sodium fluoride and Mg++ or elimination of theophylline (Fig 1) (Kissebah et al. 1972 ) which reduced to insignificant levels the adenyl cyclase and phosphodiesterase activity under assay conditions. Shreds (20-60 mg) of human adipose tissue were incubated in Krebs-Ringer bicarbonate buffer containing isoprenaline (10-5mol/l) with or without propranolol or practolol (10-5 mol/l). After incubation the shreds were rinsed and deproteinized and the C-AMP levels determined. Isoprenaline addition resulted in a sixfold increase in adipose tissue C-AMP levels, and this was abolished by propranolol and partially blocked by practolol (Fig 2) .
Cyclic Adenosine Monophosphate in Human Adipose Tissue
Subcutaneous needle biopsies of adipose tissue were obtained from obese diabetic and nondiabetic patients after an overnight fast and Shreds (200-400 mg) were freeze-clamped in liquid nitrogen immediately after biopsy, weighed and deproteinized for determination of C-AMP and glucose-6-phosphate (Bergmeyer 1965). Of 6 non-diabetic obese patients, 4 showed a fall in C-AMP levels one hour after glucose. The diabetic patients did not show reduced C-AMP levels after glucose, indeed 5 of the 6 had increased tissue C-AMP levels at one hour. In addition both glucose levels and glucose-6phosphate remained elevated up to 2 hours (Fig 3) . The various problems connected with the diagnosis and management of a patient with phmochromocytoma should be approached under the following headings: think of it, confirm it, find it, and remove it.
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Diagnosis
Many physicians have been looking for a patient with a phaeochromocytoma for years and have yet to find one, largely because they fail to think of the diagnosis. Patients presenting with 'attacks' are always a diagnostic challenge. Such attacks are more likely to be due to paroxysmal atrial tachycardia, migraine, anxiety state, dumping syndrome, hypoglycemia, epilepsy, hot flushes, &c., but a few will be due to phwochromocytoma. A typical attack usually begins with a sense of impending death, followed by pallor and palpita-tions, sometimes accompanied by angina, headache and profuse sweating, and terminating in profound weakness and exhaustion. The prevalence of these tumours in the general population is not known. Estimates in the hypertensive population vary from 0.5 to 2%. Eleven thousand people die of hypertension annually in this country (Registrar-General's Statistical Review of England and Wales for 1969, HMSO, London); if 0.5% of these die of phaochromocytoma then about 50 people die unnecessarily every year, since most of these tumours escape detection.
The physician rarely has the opportunity of observing the attack. It is therefore useful to ask the patient to keep a diary of the frequency and nature of the attacks for a period which, provided they occur frequently, can be one or two weeks. The patient is then given phenoxybenzamine 5 mg twice daily (10 mg b.d. if hypertensive) for two weeks. If the attacks are reduced in frequency, the presence of a phwochromocytoma is possible. If the attacks continue, a ,-adrenergic blocking agent (e.g. propranolol 10 mg twice daily) is given
